Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genus PLC (GB:GNS)
LSE:GNS
Holding GB:GNS?
Track your performance easily
GNS Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1,478.00p - 2,378.00p
Previous Close1,514p
Volume22.95K
Average Volume (3M)116.09K
Market Cap
£995.86M
Enterprise Value1.24B
Total Cash (Recent Filing)£42.50M
Total Debt (Recent Filing)£291.20M
Price to Earnings (P/E)126.0
Beta1.14
Next Earnings
Feb 22, 2025EPS EstimateN/A
Last Dividend Ex-Date
Nov 07, 2024Dividend Yield2.11%
Share Statistics
EPS (TTM)0.12
Shares Outstanding66,033,959
10 Day Avg. Volume223,920
30 Day Avg. Volume116,095
Standard Deviation0.09
R-Squared0.00630
Alpha-0.00578
Financial Highlights & Ratios
Price to Book (P/B)182.41
Price to Sales (P/S)1.50
Price to Cash Flow (P/CF)21.00
P/FCF Ratio20.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
2,025.00pPrice Target Upside34.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Genus plc News
PremiumCompany Announcements
Genus plc Reports Successful AGM with Shareholder Engagement
PremiumCompany Announcements
Genus plc Reports Strong Growth Amid Currency Challenges
PremiumCompany Announcements
Genus plc Reports Total Voting Rights Update
PremiumCompany Announcements
Genus plc CFO to Retire, Successor Search Underway
PremiumCompany Announcements
Genus plc Announces 2024 AGM and Report Availability
PremiumCompany Announcements
Genus plc Executives Sell Shares Post-Vesting
PremiumCompany Announcements
Genus plc CEO Sells Shares for Tax LiabilitiesBulls Say, Bears Say
Bulls Say
Market PerformanceGenus's trading update sees the business tracking in line with current market expectations for adjusted profit growth of approximately 6.5%.
Potential AcquisitionGenus could potentially become an M&A target due to its strong profile and prospects for value creation.
Regulatory ProgressGenus has submitted its Validation Report & Durability Plan to the FDA and made submissions to other regulators, crucial for commercialisation in key markets.
Bears Say
Growth ChallengesGrowth has been challenging and volatile, with recent performance only slightly higher than levels achieved several years ago.
Regulatory And Commercial ConcernsThere is concern over regulatory and commercial hurdles for the PRP programme, affecting near-term growth potential.
Stock RatingThe stock rating has been downgraded from Buy to Hold due to weaker sentiment and a cautious outlook.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.31% Insiders
13.94% Mutual Funds
― Other Institutional Investors
77.85% Public Companies and
Individual Investors
GNS FAQ
What was Genus PLC’s price range in the past 12 months?
Genus PLC lowest share price was 1478.00p and its highest was 2378.00p in the past 12 months.
What is Genus PLC’s market cap?
Currently, no data Available
When is Genus PLC’s upcoming earnings report date?
Genus PLC’s upcoming earnings report date is Feb 22, 2025 which is in 62 days.
How were Genus PLC’s earnings last quarter?
Genus PLC released its earnings results on Sep 05, 2024. The company reported -0.085p earnings per share for the quarter, missing the consensus estimate of N/A by -0.085p.
Is Genus PLC overvalued?
According to Wall Street analysts Genus PLC’s price is currently Undervalued.
Does Genus PLC pay dividends?
Genus PLC pays a Annually dividend of 21.699p which represents an annual dividend yield of 2.11%. See more information on Genus PLC dividends here
What is Genus PLC’s EPS estimate?
Genus PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genus PLC have?
Genus PLC has 66,034,880 shares outstanding.
What happened to Genus PLC’s price movement after its last earnings report?
Genus PLC reported an EPS of -0.085p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.676%.
Which hedge fund is a major shareholder of Genus PLC?
Currently, no hedge funds are holding shares in GB:GNS
---
Genus plc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.04%
12-Months-Change
Fundamentals
Return on Equity
1.41%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
Genus PLC
Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. The company generates most of its revenue from its porcine exposure, followed by its bovine exposure. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency.
---
GNS Stock 12 Month Forecast
Average Price Target
2,025.00p
▲(34.11% Upside)
Technical Analysis
Best Analysts Covering GNS
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-12.90%
reiterated a buy rating 27 days ago
Copying Patrick Roquas's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -12.90% per trade.
---